“Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs industry and market set to grow to $23bn by 2024” says Visiongain report

31 July 2019
Pharma

Visiongain has launched a new pharma report Macular Degeneration and Other Retinal Diseases Drugs Market : Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne.

The sector has obvious growth potential, since the majority of the AMD and DR patient population currently still lack any treatment options. This means that there are vast patient populations for manufacturers to target with new AMD and DR products, and new candidates in these areas can hope for fast track status from regulatory bodies.

The lead analyst of the report commented "Another question-mark that hangs over the future of the AMD and DR pharmaceuticals sector is the widespread belief that the best cure for these conditions is not biological or small-molecule drug interventions that can stabilise or reverse disease progression, but rather prevention: a therapeutic approach that can stop AMD and DR developing in the first place is widely seen as the major goal by scientists and clinicians working in the field."

Leading companies featured in the report include Acucela, Inc., Allergan Plc, Bayer AG, F. Hoffman-La Roche, Ltd., GlaxoSmithKline Pharmaceuticals, Ltd., Novartis AG, Pfizer, Inc., Valent Pharmaceuticals International, Plc and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever